Sudarshan Pharma Q1 FY27 Results (BSE: 543828)
Signal: Margin expansion
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹174.42 Cr | 20.1% | -20.8% |
| EBIT | ₹15.71 Cr | 38.2% | |
| Net profit | ₹5.86 Cr | 45.4% | |
| EPS | ₹0.23 | 43.8% | |
| EBIT margin | 9.8% |
P&L walk
Consolidated revenue increased 20.1% YoY to ₹17,441.84 lakh, while EBITDA increased 39.8% to ₹1,712 lakh and margin reached 9.8%; PAT rose 45.4% to ₹585.52 lakh, although gross margin compressed to 14.1% from 17.2% and finance cost increased 37.8%.
Research and educational content only. Not investment advice.